

JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com CIN NO. L74899DL1978PLC009181

April 18, 2023

The Department of Corporate Services- Listing

BSE Ltd,
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai-400 001
Scrip Code: 507789

The Department of Corporate Services- Listing
National Stock Exchange of India Ltd

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E) Mumbai – 400 051

Symbol: JAGSNPHARM

Subject: Submission of certificate from a Practicing Company Secretary under Regulation 40(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

We hereby submit certificate received from Practicing Company Secretary under regulation 40 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended March 31, 2023.

We request you to take the above on record.

Thanking you,

For Jagsonpal Pharmaceuticals Limited

ABHISHE K JOSHI Digitally signed by ABHISHEK JOSHI DN: cn=ABHISHEK JOSHI c=IN I=JODHPUR o=Personal e=ABHISHEKJOSHISO@GMAIL.COM Reason: E-form Filing Location: Date: 2023-04-18 11:06+05:30

Abhishek Joshi Company Secretary & Compliance Officer

Encl.: A/a

Mukesh Arora & Company

Company Secretaries



CERTIFICATE UNDER REGULATION 40(9) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

FOR THE YEAR ENDED ON 31st MARCH, 2023.

I have examined all share transfer deeds, memorandum of transfers, sub-division, consolidation, renewal, exchange or endorsement of calls/allotment monies, registers, files and other documents relating to JAGSON PAL PHARMACEUTICALS LIMITED maintained by MCS SHARE TRANSFER AGENT LIMITED pertaining to transfer of equity shares of the company for the period from 1st April, 2022 to 31st March, 2023 for the purpose of issuing a certificate as per regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 entered into by JAGSON PAL PHARMACEUTICALS LIMITED with NSE LTD and BSE LTD and based on the information provided by the company, I hereby certify that the company has delivered during year ended on 31st March, 2023:

Share certificates relating to the share trasmission deeds received during the period from 1st April, 2022 to 31st March, 2023 as entered in the memorandum of transmission and transposition have been issued within thirty days from respective date of lodgment of each deed excepting those rejected on technical grounds.

There was no case of transfer, sub-division, consolidation, renewal, exchange and for issue of duplicate shares from respective date of lodgment of each deed within this period.

Place: New Delhi Date: 17.4.2023

UDIN: F004819E000114753

FOR MUKESH ARORA & CO. COMPANY SECRETARY

(MUKESH ARORA – PROP.) F.C.S.4819

C.P. 4405